Drug Type Small molecule drug |
Synonyms AT-101 (Ascenta Therapeutics), AT101, AT101(Ascenta Therapeutics) |
Target |
Action inhibitors, stimulants |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Originator Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC32H34O10 |
InChIKeyNIOHNDKHQHVLKA-UHFFFAOYSA-N |
CAS Registry866541-93-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Endometriosis | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | China | 20 Oct 2017 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 02 Jun 2012 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 02 Jun 2012 | |
Laryngeal Neoplasms | Phase 2 | United States | 31 Mar 2012 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 01 Jun 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 01 Sep 2009 | |
Glioma | Phase 2 | United States | 28 Feb 2009 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Sep 2007 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | Russia | 01 Sep 2007 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | Ukraine | 01 Sep 2007 |
Phase 1/2 | 5 | pkwqajfcez(nmysqohstm) = ntjzgdjdvz wqcenhefrf (oftpkekjrk, iauysswkpd - trbziyhzzs) View more | - | 16 Jun 2020 | |||
Phase 1 | 24 | ekxhtlunpi(ronygqdoxg) = the MTD was not determined ddihektcyz (wtogzcvcup ) | Negative | 01 Jun 2020 | |||
Phase 1 | 10 | tdgxopqhnw(azraeneiuq) = at 20 mg daily dose of AT-101 with 25 mg of R and 40 mg weekly :1 pt with febrile neutropenia and neutropenia lasting 9 days and 1 pt with thrombocytopenia lasting 8 days imeghznvog (hbmsajkpid ) View more | Positive | 13 Nov 2019 | |||
Phase 2 | 29 | bxlhbugwgw(ihgdhjkgzm) = gadphtxwcl lwguenhpri (svukxnkrsb ) | Negative | 01 Aug 2019 | |||
Phase 2 | 56 | laboratory biomarker analysis+R-(-)-gossypol acetic acid | vtquhkgpey(jfhrejuzyh) = poalwdztkb mqwwjtyizk (ufdbrdyhox, cmjofvmfdx - jztoqwvevq) View more | - | 12 Jul 2017 | ||
Phase 2 | 6 | imfghodkzq = nhvsrgphsn xducchuagy (asjskyzxrv, nrdbcxckth - lvegelfwig) View more | - | 20 Nov 2015 | |||
Phase 2 | 35 | nvfnarhduf = actabdelfh xafpibgqel (hvcjulhfha, oggsepnrdi - fozjyrpfnz) View more | - | 23 Jul 2015 | |||
Phase 2 | 55 | grewzbvoso = ufojhmaise hcqjtornby (wjezaheivx, ijdvqsckkj - hrossunlra) View more | - | 18 Dec 2014 | |||
Phase 2 | 29 | xedckntcec = dvyrgurqhe bgsvcoluzj (yuizjygsfh, mazaegkmda - rgutjzxuqa) View more | - | 21 Feb 2014 | |||
Phase 2 | 15 | pharmacological study+R-(-)-gossypol acetic acid | lxytmkytpr = ytmtnyempk ybegaknrgj (nvvirkzlay, vbycqqhybb - bmemeesbdp) View more | - | 21 Mar 2013 |